<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

The overlooked biochemical pathway: how insulin resistance (HOMA-IR) modulates metabolic masking of prostate-specific antigen separately from body mass index

dc.contributor.authorEren, Murat Tugrul
dc.contributor.authorOzveri, Hakan
dc.date.accessioned2026-11-05T11:00:33Z
dc.date.issued2026
dc.description.abstractBackground Conventional prostate cancer screening profiles rely heavily on static serum prostate-specific antigen (PSA) thresholds, consistently overlooking the confounding impacts of the modern metabolic syndrome epidemic. This study aimed to isolate and quantify the long-term longitudinal impact of insulin resistance (HOMA-IR) and Body Mass Index (BMI) on serum PSA levels. Materials and methods We retrospectively evaluated 9095 routine annual screening records from 5,846 asymptomatic male subjects (2016-2026) with concurrent clinical data for PSA, HOMA-IR, BMI, and total testosterone. Linear Mixed-Effects Models with subject-specific random intercepts were constructed to rigorously account for intra-subject correlations across consecutive annual follow-up visits. Results Multi-variable longitudinal analysis demonstrated that while BMI exhibited a strong downward trend on baseline biomarkers (per-unit decrease of 0.018 ng/mL (p = 0.057), elevated HOMA-IR served as a statistically significant, independent biochemical marker inversely associated with serum PSA (p = 0.042). Crucially, categorical stratification revealed a highly significant, non-linear biomarker collapse: subjects in the highest cumulative metabolic burden quadrant (concurrent BMI >= 35 kg/m(2) and HOMA-IR > 3.0) exhibited a profound 34.8% reduction in age-adjusted serum PSA concentrations compared to metabolically healthy, normal-weight counterparts (p < 0.001). Conclusions Metabolic masking of serum PSA is a complex, two-pronged process characterized by physical hemodilution via tissue mass and cellular transcription-level suppression via chronic hyperinsulinemia. Transitioning away from simplistic weight-based corrections in clinical preventive screening guidelines along with systematic integration of insulin resistance profiles into individualized urological risk stratification may help eliminate this critical diagnostic blind spot.
dc.identifier.doi10.1007/s11255-026-05304-z
dc.identifier.issn0301-1623
dc.identifier.issn1573-2584
dc.identifier.urihttps://doi.org/10.1007/s11255-026-05304-z
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/10479
dc.identifier.wosWOS:001848267100001
dc.language.isoen
dc.publisherSPRINGER
dc.relation.hasversion10.1007/s11255-026-05304-z
dc.relation.ispartofINTERNATIONAL UROLOGY AND NEPHROLOGY
dc.subjectProstate-specific antigen
dc.subjectInsulin resistance
dc.subjectHOMA-IR
dc.subjectMetabolic masking
dc.subjectBody mass index
dc.subjectBiomarkers
dc.subjectOBESITY
dc.subjectUrology & Nephrology
dc.titleThe overlooked biochemical pathway: how insulin resistance (HOMA-IR) modulates metabolic masking of prostate-specific antigen separately from body mass index
dc.typeArticle
oaire.citation.editionScience Citation Index Expanded (SCI-EXPANDED)
person.identifier.ridPDX-3027-2025

Files

Collections